Tags

Type your tag names separated by a space and hit enter

Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Int Arch Allergy Immunol. 2004 Sep; 135(1):44-53.IA

Abstract

BACKGROUND

Allergen immunotherapy is a widely accepted treatment for IgE-mediated allergies. The evaluation of immunotherapy-induced IgG4 antibodies based on allergen extract is questionable because the amount of allergen-extract-specific IgG4 to individual disease-eliciting allergens cannot be determined using crude allergen extracts. In this study, we examined the specific IgE and IgG4 serum binding profiles to individual Phleum pratense allergens in grass-pollen-sensitive patients who had received grass-pollen-specific immunotherapy (SIT).

METHODS

The study included 33 patients from North-West Italy. All suffered from seasonal rhinoconjunctivitis and/or asthma. A modified "cluster" regimen of injections of a standardized aluminium-adsorbed P.pratense extract, with once-weekly visits and 10 injections for 5 weeks followed by 3 weeks of maintenance injections was instituted. Patients' sera were analyzed for specific IgE and IgG4 reactivity to individual P. pratense allergens (recombinant Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, Phl p 11, Phl p12 and native Phl p 4) and natural P. pratense extract using the Pharmacia CAP system.

RESULTS

IgE reactivities to new allergen components were not detected by CAP in treated patients after 15 weeks and a cumulative dose of approximately 65 microg of the major allergen Phl p 5. Patients lacking specific IgE reactivity towards individual allergens at the start of SIT did not produce significant levels of specific serum IgG4 to serum IgE-negative allergens. On the other hand, an increase in specific IgG4 only to allergens to which patients were previously sensitized was observed. Significant increases in specific IgG4 levels to rPhl p 1 (p < 0.05), 2 (p < (0.01), 5 (p < 0.0001), 6 (p < 0.0001), 7 (p < 0.05), 11 (p < 0.05) and nPhl p 4 (p < 0.01) were observed after P. pratense extract immunotherapy. No significant rPhl p 12-specific IgG4 antibody increase was documented after treatment.

CONCLUSION

These findings suggest that Phl p 12 was underrepresented in the extract used, as indicated by the low specific IgG4 response induced by this grass-pollen-specific vaccine. Thus, the simple detection of specific serum IgG4 antibodies a few weeks after the start of SIT could represent a valuable tool to estimate the presence of relevant allergens in a given immunotherapeutic allergen extract.

Authors+Show Affiliations

Allergy Unit, National Health Service, Cuneo, Italy. immunoway@libero.itNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15286445

Citation

Rossi, R E., and G Monasterolo. "Evaluation of Recombinant and Native Timothy Pollen (rPhl P 1, 2, 5, 6, 7, 11, 12 and nPhl P 4)- Specific IgG4 Antibodies Induced By Subcutaneous Immunotherapy With Timothy Pollen Extract in Allergic Patients." International Archives of Allergy and Immunology, vol. 135, no. 1, 2004, pp. 44-53.
Rossi RE, Monasterolo G. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol. 2004;135(1):44-53.
Rossi, R. E., & Monasterolo, G. (2004). Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. International Archives of Allergy and Immunology, 135(1), 44-53.
Rossi RE, Monasterolo G. Evaluation of Recombinant and Native Timothy Pollen (rPhl P 1, 2, 5, 6, 7, 11, 12 and nPhl P 4)- Specific IgG4 Antibodies Induced By Subcutaneous Immunotherapy With Timothy Pollen Extract in Allergic Patients. Int Arch Allergy Immunol. 2004;135(1):44-53. PubMed PMID: 15286445.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. AU - Rossi,R E, AU - Monasterolo,G, Y1 - 2004/07/30/ PY - 2003/10/14/received PY - 2004/05/17/accepted PY - 2004/8/3/pubmed PY - 2004/10/16/medline PY - 2004/8/3/entrez SP - 44 EP - 53 JF - International archives of allergy and immunology JO - Int Arch Allergy Immunol VL - 135 IS - 1 N2 - BACKGROUND: Allergen immunotherapy is a widely accepted treatment for IgE-mediated allergies. The evaluation of immunotherapy-induced IgG4 antibodies based on allergen extract is questionable because the amount of allergen-extract-specific IgG4 to individual disease-eliciting allergens cannot be determined using crude allergen extracts. In this study, we examined the specific IgE and IgG4 serum binding profiles to individual Phleum pratense allergens in grass-pollen-sensitive patients who had received grass-pollen-specific immunotherapy (SIT). METHODS: The study included 33 patients from North-West Italy. All suffered from seasonal rhinoconjunctivitis and/or asthma. A modified "cluster" regimen of injections of a standardized aluminium-adsorbed P.pratense extract, with once-weekly visits and 10 injections for 5 weeks followed by 3 weeks of maintenance injections was instituted. Patients' sera were analyzed for specific IgE and IgG4 reactivity to individual P. pratense allergens (recombinant Phl p 1, Phl p 2, Phl p 5, Phl p 6, Phl p 7, Phl p 11, Phl p12 and native Phl p 4) and natural P. pratense extract using the Pharmacia CAP system. RESULTS: IgE reactivities to new allergen components were not detected by CAP in treated patients after 15 weeks and a cumulative dose of approximately 65 microg of the major allergen Phl p 5. Patients lacking specific IgE reactivity towards individual allergens at the start of SIT did not produce significant levels of specific serum IgG4 to serum IgE-negative allergens. On the other hand, an increase in specific IgG4 only to allergens to which patients were previously sensitized was observed. Significant increases in specific IgG4 levels to rPhl p 1 (p < 0.05), 2 (p < (0.01), 5 (p < 0.0001), 6 (p < 0.0001), 7 (p < 0.05), 11 (p < 0.05) and nPhl p 4 (p < 0.01) were observed after P. pratense extract immunotherapy. No significant rPhl p 12-specific IgG4 antibody increase was documented after treatment. CONCLUSION: These findings suggest that Phl p 12 was underrepresented in the extract used, as indicated by the low specific IgG4 response induced by this grass-pollen-specific vaccine. Thus, the simple detection of specific serum IgG4 antibodies a few weeks after the start of SIT could represent a valuable tool to estimate the presence of relevant allergens in a given immunotherapeutic allergen extract. SN - 1018-2438 UR - https://www.unboundmedicine.com/medline/citation/15286445/Evaluation_of_recombinant_and_native_timothy_pollen__rPhl_p_1_2_5_6_7_11_12_and_nPhl_p_4___specific_IgG4_antibodies_induced_by_subcutaneous_immunotherapy_with_timothy_pollen_extract_in_allergic_patients_ L2 - https://www.karger.com?DOI=10.1159/000080042 DB - PRIME DP - Unbound Medicine ER -